Arv­inas’ prostate can­cer treat­ment shows hints of sig­nal — but how many pa­tients will it work for?

Arv­inas re­leased in­ter­im re­sults Thurs­day morn­ing on one of its pro­tein de­grad­er drugs for prostate can­cer ahead of a fire­side chat at the Jef­feries in­vestor con­fer­ence.

The droplet of ef­fi­ca­cy da­ta sug­gest Arv­inas’ drug can help re­duce lev­els of a bio­mark­er el­e­vat­ed in prostate can­cer, and po­ten­tial­ly shrink tu­mors, but the drug was de­signed for a spe­cif­ic (and small) sub­set of pa­tients.

In four pa­tients with metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer (mCR­PC) eval­u­at­ed for whether their tu­mors re­spond­ed to Arv­inas’ treat­ment ARV-766, which is an an­dro­gen re­cep­tor de­grad­er, one had a con­firmed par­tial re­sponse and one had an un­con­firmed par­tial re­sponse. And in 12 pa­tients eval­u­at­ed for PSA lev­els, a com­mon mark­er used to as­sess prostate can­cer, five saw their PSA lev­els drop by 50%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER